In metastatic renal cell carcinoma, the combination of sunitinib with an α-GITR agonist can be used to effectively improve the tumor immune microenvironment and to activate the cytotoxicity of CD8+ T cells and NK cells to prevent liver metastasis (8). Here, CD8A is linked to neoplasm.